羟氯喹视网膜毒性停药后的纵向变化
结果显示早期(1期)病变多稳定甚至部分功能改善,而3、4期病变在视力和视野上继续恶化,提示早期发现并及时停药可能阻止病变进展。
要点
- 停药后视网膜结构与功能并非普遍稳定,变化幅度与停药时病变严重程度相关。
- 1期 eyes 的 mfERG R1/R2 比值显著改善,而更高级别 eyes 无显著变化。
- 3、4期 eyes 视力显著下降,3期 eyes 视野也恶化,提示晚期病变继续进展。
核心结论
- 确诊羟氯喹视网膜病变的眼在停药后视网膜结构与功能并不普遍稳定,而是出现与停药时严重程度相关的一系列变化。
- 仅存细微局限病变的眼在停药后多稳定,并可能显示部分功能改善;而病变较重的眼继续进展。
- 这些发现提示羟氯喹视网膜病变可能需要早期发现并及时停药,以阻止病变进展并优化长期结局。
研究设计与样本
- 研究眼(n=44)根据停药时谱域OCT黄斑扫描的定性分级分为4个严重程度分期。
- 计算并比较停药时与末次随访之间结局指标的变化,并在不同严重程度分期的眼之间进行比较。
主要发现
- 研究眼按OCT标准分为:1期(局限于旁中心凹的细微改变;n=14)、2期(旁中心凹明确的局限改变;n=17)、3期(广泛的旁中心凹改变;n=7)、4期(中心凹受累;n=6)。
- 随访期间视力在1期和2期眼保持稳定,但在3期和4期眼显著下降;Humphrey视野在1期和2期眼稳定,但在3期眼恶化。
- 停药后1期眼的mfERG R1/R2比值显著改善(平均变化=-0.86±0.79,P=0.03),而更高级别眼无显著变化。
- 所有分期的眼均出现谱域OCT 9个ETDRS亚区中≥1个的黄斑厚度下降,其中2期眼在大多数亚区(9个中的8个)显示变薄。
- 在可测量中心凹椭圆体带岛的眼(2期9/17眼,3期7/7眼)中,2期6/9眼(67%)和3期6/7眼(86%)观察到中心凹椭圆体带长度进行性缩短。
关键数值与推荐
- 研究眼按停药时谱域OCT黄斑扫描定性分级分为4期:1期(局限于旁中心凹的细微改变;n=14)、2期(旁中心凹明确的局限改变;n=17)、3期(广泛的旁中心凹改变;n=7)、4期(中心凹受累;n=6)。
临床怎么用
- 对羟氯喹视网膜病变应尽早发现并及时停药,以阻止病变进展并优化长期结局。
- 停药后仍需按病变严重程度进行多模态影像和视功能随访,晚期病变可能继续进展。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To characterize functional and structural changes in hydroxychloroquine (HCQ) retinal toxicity after drug cessation. METHODS: Twenty-two patients (91% female; mean age 58.7 ± 11.4 years; mean duration of HCQ treatment 161.1 ± 90 months; mean dose 5.9 ± 1.9 mg/kg) with detected HCQ retinopathy were monitored for 6 months to 82 months after HCQ cessation with multimodal imaging including spectral domain optical coherence tomography and fundus autofluorescence imaging at 488 nm (standard) and 787 nm (near-infrared autofluorescence). Tests of visual function including visual acuity, Humphrey visual field testing, and multifocal electroretinography (mfERG) were performed. Study eyes were categorized into four separate severity stages by qualitative grading of spectral domain optical coherence tomography macular scans taken at the time of HCQ cessation. Changes in outcome measures between drug cessation and last follow-up visit were computed and compared between eyes of different severity stages. RESULTS: Study eyes (n = 44) were categorized based on optical coherence tomography criteria into: Stage 1 (subtle changes confined to parafoveal region; n = 14), Stage 2 (clear localized changes in parafovea; n = 17), Stage 3 (extensive parafoveal changes; n = 7), and Stage 4 (foveal involvement, n = 6). Visual acuity measurements across follow-up were stable in Stage 1 and Stage 2 eyes but decreased significantly in Stage 3 and 4 eyes. Humphrey visual field measures were also stable in stages 1 and 2 but deteriorated in Stage 3 eyes. mfERG testing demonstrated significant improvement in the R1/R2 ratio after HCQ cessation in Stage 1 eyes (mean change = -0.86 ± 0.79, P = 0.03) but did not change significantly in eyes of higher stages. Decreases in macular thickness in ≥1 of 9 Early Treatment Diabetic Retinopathy Study subfields on spectral domain optical coherence tomography were found in eyes of all stages, with Stage 2 eyes demonstrating thinning in most subfields (eight of nine subfields). In eyes with a measurable central foveal ellipsoid zone band island (9 of 17 Stage 2 eyes and 7 of 7 Stage 3 eyes), progressive decrease in the foveal ellipsoid zone band length was observed in 6 of 9 (67%) Stage 2 eyes and 6 of 7 (86%) Stage 3 eyes. Changes indicative of progressing retinopathy were detected in 17% of Stage 1 eyes, 46% of Stage 2 eyes, and 43% of Stage 3 eyes on standard fundus autofluorescence imaging, and in 17% of Stage 1 eyes, 38% of Stage 2 eyes, and 14% of Stage 3 eyes on near-infrared autofluorescence imaging. CONCLUSION: Eyes with detected HCQ retinopathy do not demonstrate general stability in retinal structure and function after HCQ cessation but instead demonstrate a range of changes during follow-up whose magnitudes correlate with retinopathy severity at the time of cessation. After cessation, eyes with only subtle and localized retinopathy were mostly stable and may show some functional improvement, whereas more severely affected eyes continued to progress. These findings provide evidence that early detection and prompt cessation in HCQ retinopathy may be needed to arrest retinopathy progression and to optimize long-term outcomes.
引用
- Allahdina AM, Chen KG, Alvarez JA, et al. LONGITUDINAL CHANGES IN EYES WITH HYDROXYCHLOROQUINE RETINAL TOXICITY. Retina. 2019. PMID: 30741731. doi:10.1097/IAE.0000000000002437
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。